Subtle Medical, Inc., a pioneer in AI-powered medical imaging solutions, has announced positive results from a proof-of-concept study conducted in collaboration with Bayer, a global leader in radiology and contrast media. The study evaluated Subtle Medical’s investigational SubtleGAD™ technology, an AI-driven algorithm designed to generate high-quality, full-dose contrast-enhanced MRI images from significantly reduced doses of gadolinium-based contrast agents. The trial included 39 patients undergoing brain MRI at five leading U.S. medical centers: Mayo Clinic, MD Anderson Cancer Center, OSF St. Francis Hospital in Peoria, the University of Massachusetts, and The Pennsylvania State University. Each patient first received a standard full-dose contrast injection followed by a reduced-dose scan. SubtleGAD™ used deep learning to enhance the low-dose MRI data and synthesize images resembling those obtained with full contrast. Key findings showed strong similarity between the AI-synthesized reduced-dose images and standard full-dose images in critical diagnostic parameters, including contrast enhancement, border delineation, and internal lesion morphology. These results suggest that SubtleGAD™ can maintain diagnostic image quality while significantly lowering gadolinium exposure. Dr. Ajit Shankaranarayanan, Chief Product Officer at Subtle Medical, said the findings mark a meaningful advancement in patient safety and imaging innovation. “This study validates SubtleGAD™ as a promising tool to reduce gadolinium dose without sacrificing diagnostic confidence,” he said. “For patients, this means lower exposure to potentially harmful contrast agents. For radiologists, it means maintaining image quality and diagnostic accuracy. We’re proud to partner with Bayer on this mission-driven research.” Bayer has decided to extend its collaboration with Subtle Medical into the next phase of clinical development for SubtleGAD™. The focus will now shift to broader clinical trials aimed at evaluating the technology’s real-world performance and supporting regulatory milestones for reduced-dose imaging protocols. This partnership builds on Subtle Medical’s expanding portfolio of AI-enhanced imaging solutions. Its FDA-cleared and CE-marked Subtle-ELITE™ platform includes SubtleHD™, SubtleSYNTH™, and SubtleALIGN™, and its SubtlePET™ solution is also gaining traction. These AI tools are already deployed on over 1,000 imaging scanners worldwide, enabling faster scans, improved image quality, and enhanced patient care—all without requiring new hardware. With Bayer’s expertise in contrast media and Subtle Medical’s leadership in AI-driven image optimization, the collaboration reflects a growing industry focus on balancing diagnostic accuracy with patient safety and imaging efficiency.